Skip to Main Content
Back to News

Lobbying Update: $290,000 of MYRIAD GENETICS INC. lobbying was just disclosed

None

$290,000 of MYRIAD GENETICS INC. lobbying was just disclosed, from Q4 of 2024, in a new Lobbying Disclosure Act filing.

This included lobbying on issues like:

"S.708 - legislation to require a dear Medicaid director letter concerning precision medicine for depression. Regulations governing Medicare Advantage plans and the use of prior authorization."

You can find more data on corporate lobbying on Quiver Quantitative.

MYGN Insider Trading Activity

MYGN insiders have traded $MYGN stock on the open market 7 times in the past 6 months. Of those trades, 0 have been purchases and 7 have been sales.

Here’s a breakdown of recent trading of $MYGN stock by insiders over the last 6 months:

  • COLLEEN F REITAN sold 46,012 shares for an estimated $1,285,851
  • PAUL J DIAZ (President and CEO) has made 0 purchases and 2 sales selling 30,000 shares for an estimated $744,750.
  • MARGARET ANCONA (SVP, Chief of Staff) sold 11,538 shares for an estimated $320,987
  • HEINRICH DREISMANN sold 10,000 shares for an estimated $270,520
  • RASHMI KUMAR sold 7,500 shares for an estimated $210,075
  • DALE MUZZEY (Chief Scientific Officer) sold 2,100 shares for an estimated $54,961

To track insider transactions, check out Quiver Quantitative's insider trading dashboard.

MYGN Hedge Fund Activity

We have seen 127 institutional investors add shares of MYGN stock to their portfolio, and 98 decrease their positions in their most recent quarter.

Here are some of the largest recent moves:

To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.

This article is not financial advice. See Quiver Quantitative's disclaimers for more information.

Add Quiver Quantitative to your Google News feed.Google News Logo

Suggested Articles